偷家战术,无码激情AAAAA片-区区,A∨在线视频播放,JZZIJZZIJ在线观看亚洲熟妇

丹麥諾維信Novozymes   
丹麥諾維信公司（Novozymes A/S）成立于1941年,是領(lǐng)導(dǎo)世界酶制劑和微生物領(lǐng)域產(chǎn)品的公司，世界市場(chǎng)份額超過(guò)45%，產(chǎn)品銷(xiāo)售遍及全球130多個(gè)國(guó)家。諾維信總部設(shè)在哥本哈根，在30個(gè)國(guó)家建立了分支機(jī)構(gòu)，員工總數(shù)5000人。2007年諾維信全球營(yíng)業(yè)收入74.38億丹麥克朗，凈利潤(rùn)10.42億丹麥克朗。該公司是丹麥在華最大投資企業(yè)之一，自1994年起累計(jì)在中國(guó)投資超過(guò)2億美元，在天津經(jīng)濟(jì)技術(shù)開(kāi)發(fā)區(qū)和北京中關(guān)村科技園區(qū)分別建立了酶制劑生產(chǎn)基地和中國(guó)首家由外商投資設(shè)立的生物技術(shù)研發(fā)中心。位于天津經(jīng)濟(jì)技術(shù)開(kāi)發(fā)區(qū)的諾維信（中國(guó)）生物技術(shù)有限公司是諾維信集團(tuán)全球三大酶制劑戰(zhàn)略生產(chǎn)基地之一，2008年該公司在天津又新增投資3億人民幣。諾維信公司在江蘇太倉(cāng)投資建設(shè)的蘇州宏達(dá)制酶公司四期擴(kuò)建工程2008年底前已完工并投入使用，使之成為目前全球最大的酶發(fā)酵生產(chǎn)基地，主要生產(chǎn)用于生物乙醇工業(yè)使用的酶制劑。諾維信公司從2006年6月開(kāi)始與中國(guó)中糧集團(tuán)進(jìn)行第二代生物乙醇的技術(shù)合作，通過(guò)諾維信提供的酶技術(shù)，將玉米秸稈、木質(zhì)素纖維素等原料變?yōu)榭砂l(fā)酵糖，再變?yōu)楣I(yè)乙醇。

以糧食和經(jīng)濟(jì)作物為原料的第一代燃料乙醇生產(chǎn)從長(zhǎng)遠(yuǎn)看具有規(guī)模限制和不可持續(xù)性，而利用秸稈、禾草和森林工業(yè)廢棄物等非食用纖維素生產(chǎn)乙醇，不存在與人爭(zhēng)糧的問(wèn)題，以纖維素為原料的第二代“非糧”生物燃料乙醇是決定未來(lái)大規(guī)模替代石油的關(guān)鍵。諾維信公司從2001年就開(kāi)始研究該項(xiàng)技術(shù)，目前在生產(chǎn)第二代生物乙醇的酶發(fā)酵技術(shù)上目前處于世界領(lǐng)先水平，現(xiàn)有150人從事該領(lǐng)域的專(zhuān)門(mén)研究，并與包括世界生物能源領(lǐng)先企業(yè)美國(guó)ICM等50多家相關(guān)機(jī)構(gòu)建立了研發(fā)聯(lián)系。諾維信公司在酶領(lǐng)域的技術(shù)在2008年開(kāi)始變得相對(duì)成熟，丹麥DONG能源公司今年9月投產(chǎn)的第二代生物乙醇提煉廠就使用了諾維信公司的酶技術(shù)。諾維信公司希望能在2010年實(shí)現(xiàn)第二代生物乙醇的規(guī)?；a(chǎn)。

諾維信公司非常關(guān)注中國(guó)能源市場(chǎng)，并希望該技術(shù)能在中國(guó)發(fā)展生物燃料乙醇產(chǎn)業(yè)，尤其是第二代“非糧”生物乙醇產(chǎn)業(yè)中得到應(yīng)用，為中國(guó)發(fā)展清潔能源和節(jié)能減排提供技術(shù)支持。謝杭生大使向Steen Riisgaard先生通報(bào)了當(dāng)前國(guó)內(nèi)經(jīng)濟(jì)形勢(shì)和應(yīng)對(duì)全球經(jīng)濟(jì)衰退的政策措施,以及中國(guó)在能源發(fā)展領(lǐng)域的政策，對(duì)諾維信公司的中國(guó)發(fā)展戰(zhàn)略表示支持，駐丹使館在此過(guò)程中愿提供必要的幫助。

Novozymes is a biotech-based world leader in industrial enzymes and microorganisms. The company produces and sells more than 500 enzyme products in 120 countries. Since 1941, Novozymes has introduced almost every new industrial enzyme on the market, making the company the word’s largest manufacturer of enzymes today.
 Novozymes is the biotech-based world leader in enzymes and microorganisms. We strive towards better business, cleaner environment and better lives. Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance in all areas.

Environment-friendly products
Novozymes' more than 600 products are a key player in the production of thousands of products you use in your everyday life - from the textiles in your clothes to the food you eat.

In more than 40 different industries and 130 countries, our biological solutions improve industrial performance and quality while at the same time saving on water, energy, raw materials and waste.

Solutions for the future
In partnership with customers, technology leaders and other stakeholders, Novozymes' 4,000 employees use nature's diversity and our advanced biotech platform to make these unique qualities available to businesses everywhere.
We imagine a future where our biological solutions create the necessary balance between better business, cleaner environment and better lives.
To get there:

We will drive a significant expansion of the market for industrial biotechnology with enzymes and micro organisms as our basis.

We will find new and improved solutions to serve the market for biopharmaceuticals.

We will achieve double digit growth with a leadership position in all markets served.

Customers and partners throughout the world will seek our collaboration because of what we do and how we do it.

People from all over the world will want to work for us because of what we do and how we do it.

Society will be inspired by our work to choose biological solutions as a key part of the future.
Novozymes to acquire Indian enzyme business

Novozymes acquires Biocon’s enzyme business for an agreed purchase price equivalent to DKK 551 million. Novozymes thereby strengthens its position in India.

Biocon is one of India's leading biotechnology companies, specialising in biopharmaceuticals, contract research, clinical research and enzymes. The company is the leading enzyme player in India, and the enzyme business includes a broad range of industrial enzymes, food additives and process aids. Further, Biocon holds a leading position in the global enzymes market for the juice and wine industries.

“The acquisition of Biocon’s enzyme business provides an important step for Novozymes in strengthening our position on the Indian market, which we believe has an attractive growth potential. The activities of Biocon have a good strategic fit to our existing enzyme business”, says CEO of Novozymes, Steen Riisgaard, “We see several interesting market opportunities combined with synergy potential, making this a very interesting acquisition“, he continues.
AWMB@novozymes.com